SPRUCE BIOSCIENCES

Company snapshot

Spruce Biosciences is a clinical stage biopharmaceutical company focused on developing novel therapies for rare diseases affecting the endocrine system.

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 US patent(s) indexed to this assignee profile.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for SPRUCE BIOSCIENCES. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for SPRUCE BIOSCIENCES.

1. Jun 8, 2026 Clinical update

   Tralesinidase alfa (TA) — Phase 3

2. Jun 5, 2026 Clinical update

   Tildacerfont/Placebo — Phase 2

3. May 23, 2026 Clinical update

   SPR001 — Phase 2

4. May 23, 2026 Clinical update

   Tildacerfont — Phase 2

5. May 23, 2026 Clinical update

   Tildacerfont — Phase 2

View all clinical trial activity →

• What is SPRUCE BIOSCIENCES?

  Spruce Biosciences is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker SPRB. Primary therapeutic focus areas include Congenital Adrenal Hyperplasia, Polycystic Ovary Syndrome, MPS IIIB. NovaPharmaNews links 5 clinical program(s), 0 d

• Is SPRUCE BIOSCIENCES publicly traded?

  Yes. SPRUCE BIOSCIENCES is listed with ticker SPRB on NYSE per SEC EDGAR records linked on this profile.

• What drugs does SPRUCE BIOSCIENCES develop or market?

  We link 3 drug profile(s) where SPRUCE BIOSCIENCES is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/spruce-biosciences-inc#company-drugs.

• What are the latest developments for SPRUCE BIOSCIENCES?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does SPRUCE BIOSCIENCES focus on?

  SPRUCE BIOSCIENCES focuses on Congenital Adrenal Hyperplasia, Polycystic Ovary Syndrome, MPS IIIB based on our analysis of their pipeline programs and drug development activities.